Stock vs Stock Comparison

Boston Scientific Corporation vs Eli Lilly and Company

LLY wins the Tale of the Tape 5–3.

BSX$47.68
LLY$1064.15

🏆 Tale of the Tape

35
BSXLLY
14.4%Profitability (Net Margin)31.7%
20.2xValuation (P/E)39.2x
7.7%Efficiency (ROIC)30.4%
7/9Health (Piotroski F)7/9
3.9Safety (Altman Z)7.8
19.9%Growth (Rev YoY)44.7%
-1.50Risk (Sharpe 1Y)0.61
0.78xBalance Sheet (D/E)3.24x
3.37%FCF Yield0.68%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

-0.076
252-Day Correlation
-0.265
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricBSXLLY
Market Cap$71.8B$985.4B
P/E Ratio20.2x39.2x
Forward P/E12.9x24.8x
P/B2.78x31.65x
Dividend Yield0.63%
Beta0.620.48

Quantitative Metrics

MetricBSXLLY
DCF Fair Value$75.06$296.11
DCF Upside+18.8%-68.2%
Piotroski F7/97/9
Altman Z3.887.84
Beneish M-2.52-1.91
FCF Yield3.37%0.68%
Net Debt/EBITDA1.8x1.1x
ROIC7.7%30.4%
WACC9.1%7.8%
ROIC – WACC-1.4pp22.5pp
Gross Margin69.0%83.0%
Net Margin14.4%31.7%
Rev Growth YoY19.9%44.7%
Sharpe (1Y)-1.500.61
Max Drawdown 3Y
FCF Payout Ratio90%

BSX Price

Loading chart...

LLY Price

Loading chart...

ETF Exposure

BSX found in:

IHI4.20%
XLV1.58%
XHE1.40%
VHT1.38%
MGK0.44%
SCHV0.38%
VUG0.26%
SPLG0.25%
IWD0.25%
IVV0.24%
ITOT0.21%
VONV0.21%
RSP0.20%
ESGV0.19%
SCHX0.18%
SCHB0.17%
SPYG0.16%
VFMV0.16%
ACWI0.15%
VOO0.14%
URTH0.13%
SPY0.13%
VONE0.13%
SPTM0.12%
VTI0.12%
QUS0.12%
SPYV0.10%
VT0.08%
IWF0.06%
VONG0.05%
ONEO0.02%

LLY found in:

XLV15.40%
IYH13.72%
VHT12.15%
VIG3.33%
SCHG3.17%
QUAL2.92%
MGK2.82%
IWF2.66%
VONG2.42%
SPYG2.36%
VUG2.31%
IVW2.23%
QUS1.95%
XPH1.90%
ESGV1.48%
DGRW1.46%
IVV1.46%
SCHX1.34%
SPY1.29%
ITOT1.29%
SCHB1.25%
VFQY1.23%
VOO1.20%
SPTM1.20%
VTI1.14%
VONE1.14%
SPLG1.10%
ARKG1.04%
URTH0.99%
ACWI0.87%
VT0.66%
VFMO0.46%
RSP0.20%
ONEO0.02%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

BSX vs LLY: Head-to-Head Analysis

Boston Scientific Corporation (BSX) and Eli Lilly and Company (LLY) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, LLY leads 5–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, BSX generates a return on invested capital (ROIC) of 7.7% compared to LLY's 30.4%. This suggests LLY is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between BSX and LLY is -0.076, indicating low correlation, making them an effective diversification pair in a portfolio context.

BSX appears in 31 ETFs tracked by SecuritiesDB, while LLY appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, BSX or LLY?

Our quantitative analysis compares BSX and LLY across nine fundamental dimensions. LLY wins the Tale of the Tape 5–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are BSX and LLY correlated?

The 252-day correlation between BSX and LLY is -0.076. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.